Evidence map›Paper›PMID 36797091›Full record

ArticleHuman immunology2023

Impact of HLA polymorphisms on the susceptibility to SARS-CoV-2 infection and related mortality in patients with renal replacement therapy.

Omer Faruk Akcay, Haci Hasan Yeter, Yasemin Unsal, Emre Yasar, Sevim Gonen, Ulver Derici

Open access · greenAbstract read
In one paragraph

Article in Human immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Omer Faruk AkcayGazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey. Electronic address: omerfaruk_akcay@yahoo.com.
Haci Hasan YeterSivas Numune State Hospital, Department of Nephrology, Sivas, Turkey.
Yasemin UnsalGazi University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
Emre YasarGazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey.
Sevim GonenGazi University Faculty of Medicine, HLA Tissue Typing Laboratory, Ankara, Turkey.
Ulver DericiGazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey.
Gazi University · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection could present in a clinical spectrum of varying severity. Human leukocyte antigen (HLA) is a crucial component of the viral antigen presentation pathway and immune response to the virus. Therefore, we aimed to assess the impact of HLA allele polymorphisms on the susceptibility to SARS-CoV-2 infection and related mortality in Turkish kidney transplant recipients and wait listed patients, along with clinical characteristics of the patients. We analysed data from 401 patients with clinical characteristics according to presence (n = 114, COVID+) or absence of SARS-CoV-2 infection (n = 287, COVID-) who had previously been HLA typed to support transplantation. The incidence of coronavirus disease-19 (COVID-19) was 28 %, and the mortality rate was 19 % in our wait listed/ transplanted patients. Multivariate logistic regression analysis showed that a significant HLA association between HLA- B*49 (OR = 2.57, 95 % CI, 1.13-5.82; p = 0.02) and HLA- DRB1*14 (OR = 2.48, 95 % CI, 1.18-5.20; p = 0.01) with SARS-CoV-2 infection. Besides, in COVID + patients, HLA-C*03 was correlated to mortality (OR = 8.31, 95 % CI, 1.26-54.82; P = 0.03). The new finding from our analysis suggests that HLA polymorphisms could be associated with the occurrence of SARS-CoV-2 infection and COVID-19 mortality in Turkish patients with renal replacement therapy. This study may provide new information for the clinician to identify and manage sub-populations at risk in the setting of the current COVID-19 pandemic.

Indexed as

COVID-19Histocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA-B AntigensHumansPandemicsRenal Replacement TherapySARS-CoV-2Histocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA-B AntigensCoronavirusCOVID‐19Human leukocyte antigenPandemicSARS-CoV2

Identifiers

PMID36797091
PMCPMC9899785
OpenAlexW4319319564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.